Cough/Cold, Analgesic Patch Sales Ease Pain Of Private Label Growth In OTCs
Topical analgesic sales grew double digits in 2017 on innovation and adhesive patch launches, helping drive 2.1% growth of US manufacturers' OTC drug sales in 2017 to $21.2bn, Kline & Co. independent consultant Laura Mahecha says. But private label continues to outpace branded product sales growth.
You may also be interested in...
Sales of dietary supplements promoted as non-drug alternative remedies and stocked nearby OTC in stores grew almost 12% in 2017, says Kline analyst Laura Mahecha. Retailers began co-stocking the about five years ago but in many cases the supplements currently have primary placement on shelves.
Sponsors can point consumers to video displays, website information and mobile apps to help them choose products that have been switched from Rx to OTC. Draft guidance on innovative switch applications to be followed by rule-making in near future.
Acne cream, gels, lotions and patches showed 33% unit growth in independent stores in 2015-2017, compared to 16.7% growth in chain pharmacies, according to Hamacher Resource Group.“You have to choose your partners wisely and choose your categories. If you do that well, do your homework, I think there’s an opportunity” to grow sales in independent pharmacies, says Hamacher VP Dave Wendland.